Hybrid molecules with a dual mode of action: Dream or reality?

Accounts of Chemical Research

Volumn 41, Issue 1, 2008, Pages 69-77

  Meunier, Bernard ^a,b  

^a Palumed   (France)

^b LCC LABORATOIRE DE CHIMIE DE COORDINATION   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOQUINOLINE DERIVATIVE; ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; COMBINATORIAL CHEMISTRY; COMPUTER AIDED DESIGN; DRUG DESIGN; HUMAN; MOLECULAR WEIGHT;

AMINOQUINOLINES; ANTIMALARIALS; ANTINEOPLASTIC AGENTS; COMBINATORIAL CHEMISTRY TECHNIQUES; COMPUTER-AIDED DESIGN; DRUG DESIGN; HUMANS; MOLECULAR STRUCTURE; MOLECULAR WEIGHT;

EID: 38949125112     PISSN: 00014842     EISSN: None     Source Type: Journal    
DOI: 10.1021/ar7000843     Document Type: Article

References (75)

1. Dickson, M.; Gagnon, J. P. Key factors in the rising cost of new drug discovery and development. Nat. Rev. Drug Discovery 2004, 3, 417-429.
2. DiMasi, J.; Hansen, R.; Grabowski, H. The price of innovation: New estimates of drug development costs. J. Health Econ. 2003, 22, 151-185.
3. Adams, C. P.; Brantner, V. V. The real cost of drug development. Drug Dev. 2006, 25, 23-24.
4. Payne, D. J.; Gwynn, M. N.; Holmes, D. J.; Pompliano, D. L. Drugs for bad bugs; confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discovery 2007, 6, 29-40.
5. Chan, P. F.; Holmes, D. J.; Payne, D. J. Findings the gems using genomic discovery: Antibacterial drug discovery strategies - The successes and the challenges. Drug Discovery Today 2004, 1, 519-527.
6. Yee, A.; Pardee, K.; Christendat, D.; Savchenko, A.; Arrowsmith, C. H. Structural proteomics: Toward high-throughput structural biology as a tool in functional genomics. Acc. Chem. Res. 2003, 36, 183-189.
7. Thomas, G. L.; Wyatt, E. E.; Spring, D. R. Enriching chemical space with diversity-oriented synthesis. Curr. Opin. Drug Discovery Dev. 2006, 9, 700-712.
8. Tan, D. S. Diversity-oriented synthesis: Exploring the intersections between chemistry and biology. Nat. Chem. Biol. 2005, 1, 74-84.
9. Burke, M. D.; Berger, E. M.; Schreiber, S. L. A synthesis strategy yielding skeletally diverse small molecules combinatorially. J. Am. Chem. Soc. 2004, 126, 14095-14104.
10. Koehn, F. E.; Carter, G. T. The evolving role of natural products in drug discovery. Nat. Rev. Drug Discovery 2005, 4, 206-220.
11. Breinbauer, R.; Vetter, I. R.; Waldmann, H. Angew. Chem., Int. Ed. 2002, 41, 2879-2890.
12. Paterson, I.; Anderson, E. A. The renaissance of natural products as drug candidates. Science 2005, 310, 451-453.
13. Newman, D. J.; Cragg, G. M. Natural products sources of new drugs over the last 25 years. J. Nat. Prod. 2007, 70, 461-477.
14. Floss, H. G. Combinatorial biosynthesis - Potential and problems. J. Biotechnol. 2006, 124, 242-257.
15. Huwe, C. M. Synthetic library design. Drug Discovery Today 2006, 11, 763-767.
16. Lepre, C. A.; Moore, J. M.; Peng, J. W. Theory and applications of NMR-based screening in pharmaceutical research. Chem. Rev. 2004, 104, 3641-3675.
17. Debusk, A. G. Metabolic aspects of chemical genetics. Adv. Enzymol. Relat. Subj. Biochem. 1956, 17, 393-476.
18. Schreiber, S. L. Chemical genetics resulting from a passion for synthetic organic chemistry. Bioorg. Med. Chem. 1998, 6, 1127-1152.
19. Walsh, D. P.; Chang, Y. T. Chemical genetics. Chem. Rev. 2006, 106, 2476-2530.
20. Kodadek, T.; Bachhawat-Sikder, K. Optimized protocols for the isolation of specific protein-binding peptides or peptoids from combinatorial libraries displayed on beads. Mol. Biosyst. 2006, 2, 25-35.
21. Glover, D. J.; Lipps, H. J.; Jans, D. A. Towards safe, non-viral therapeutic gene expression in humans. Nat. Rev. Genet. 2005, 6, 299-310.
22. O'Driscoll, L. The emerging world of microRNAs. Anticancer Res. 2006, 26, 4271-4278.
23. Bumcrot, D.; Manoharan, M.; Koteliansky, V.; Sah, D. W. RNAi therapeutics: A potential new class of pharmaceutical drugs. Nat. Chem. Biol. 2006, 2, 711-719.
24. Shi, L.; Sings, H. L.; Bryan, J. T.; Wang, B.; Wang, Y.; Mach, H.; Kosinski, M.; Washabaugh, K. W.; Sitrin, R.; Barr, E. Clin. Pharmacol. Ther. 2007, 81, 259-264.
25. Holden, C. Controversial marrow cells coming into their own. Science 2007, 315, 760-761.
26. Daley, G. O. The ISSCR guidelines for human embryonic stem cell research. Science 2007, 315, 603-604.
27. Mullin, R. Priming the pipeline. Chem. Eng. News 2004, February 16, 23-42.
28. Catlin, A.; Cowan, C.; Heffler, S.; Washington, B. National health expenditure accounts team. National health spending in 2005: The slowdown continues. Health Aff. (Millwood) 2007, 26, 142-153.
29. Geborek, P.; Nitelius, E.; Noltorp, S.; Petri, H.; Jacobsson, L.; Larson, L.; Saxne, T.; Leden, I. Population based studies of biological antirheumatic drug use in southern Sweden: Comparison with pharmaceutical sales. Ann. Rheum. Dis. 2005, 64, 1805-1807.
30. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997, 23, 3-25.
31. Martin, Y. C. A bioavailability score. J. Med. Chem. 2005, 48, 3164-3170.
32. Vieth, M.; Sutherland, J. J. Dependence of molecular properties on proteomic family for marketed oral drugs. J. Med. Chem. 2006, 49, 3451-3453.
33. Lipinski, C.; Hopkins, A. Navigating chemical space for biology and medicine. Nature 2004, 432, 855-861.
34. Fink, T.; Reymond, J. L. Virtual exploration of the chemical universe up to 11 atoms of C, N, O, F: Assembly of 26.4 million structures (110.9 million stereoisomers) and analysis for new ring systems, stereochemistry, physicochemical properties, compound classes and drug discovery. J. Chem. Inf. Model. 2007, 47, 342-353.
35. Ettmayer, P.; Amidon, G. L.; Clement, B.; Testa, B. Lessons learned from marketed and investigational prodrugs. J. Med. Chem. 2004, 47, 2393-2404.
36. Rees, D. C.; Congreve, M.; Murray, C. W.; Carr, R. Fragment-based lead discovery. Nat. Rev. Drug Discovery 2004, 3, 660-672.
37. Guiseppone, N.; Lehn, J. M. Protonic and temperature modulation of constituent expression by component selection in a dynamic combinatorial library of imines. Chemistry 2006, 12, 1715-1722.
38. Sausville, E. A.; Stein, R. W.; Peisach, J.; Horwitz, S. B. Properties and products of the degradation of DNA by bleomycin and iron(II). Biochemistry 1978, 17, 2746-2754.
39. Burger, R. M. Cleavage of nucleic acids by bleomycin. Chem. Rev. 1998, 98, 1153-1169.
40. 2, the major catabolite of the antitumor agent bleomycin. J. Am. Chem. Soc. 2006, 124, 9476-9488.
41. Becker, A.; Chow, M. S.; Kemsley, J. N.; Lehnert, N.; Solomon, E. I. Direct hydrogen abstraction by activated bleomycin: an experimental and computational study. J. Am. Chem. Soc. 2006, 128, 4719-4733.
42. Kumar, D.; Hirao, H.; Shaik, S.; Kozlowski, P. M. Proton-shuffle mechanism of O-O activation for formation of a high-valent oxo-iron species of bleomycin. J. Am. Chem. Soc. 2006, 128, 16148-16158.
43. 5, a single oxygen donor. Biochem. Biophys. Res. Commun. 1986, 136, 1013-1020.
44. Pratviel, G.; Bernadou, J.; Meunier, B. Evidence for high-valent iron-oxo species active in the DNA breaks mediated by iron-bleomycin. Biochem. Pharmacol. 1989, 38, 133-140.
45. Ding, L.; Etemad-Moghadam, G.; Meunier, B. Oxidative cleavage of DNA mediated by hybrid metalloporphyrin-ellipticine molecules and functionalized metalloporphyrin precursors. Biochemistry 1990, 29, 7868-7875.
46. Ding, L.; Etemad-Moghadam, G.; Cros, S.; Auclair, C.; Meunier, B. Syntheses and in vitro evaluation of "cationic metalloporphyrin- ellipticine" molecules having a high affinity for DNA. J. Med. Chem. 1991, 34, 900-906.
47. Meshnick, S. R.; Taylor, T. E.; Kamchonwongpaisan, S. Artemisinin and the antimalarial endoperoxides: From herbal remedy to targeted chemotherapy. Microbiol. Rev. 1996, 60, 301-315.
48. Hsu, E. Reflections on the "discovery" of the antimalaria qinghao. Br. J. Clin. Pharmacol. 2006, 61, 666-670.
49. Robert, A.; Meunier, B. Characterization of the first covalent adduct between artemisinin and a heme model. J. Am. Chem. Soc. 1997, 119, 5968-5969.
50. Robert, A.; Cazelles, J.; Meunier, B. Characterization of the alkylation product of heme by the antimalarial drug artemisinin. Angew. Chem., Int. Ed. 2001, 40, 1954-1957.
51. Robert, A.; Benoit-Vical, F.; Claparols, C.; Meunier, B. The antimalarial drug artemisinin alkylates heme in infected mice. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 13676-13680,
52. and Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 3943 for the corrected Figure 1.
53. Laurent, S. A.; Robert, A.; Meunier, B. C10-modified artemisinin derivatives: Efficient heme-alkylating agents. Angew. Chem., Int. Ed. 2005, 44, 2060-2063.
54. Cazelles, J.; Robert, A.; Meunier, B. Alkylating capacity and reaction products of antimalarial trioxanes after activation by a heme model. J. Org. Chem. 2002, 67, 609-619.
55. Wiseman, V.; Kim, M.; Mutabingwa, T. K.; Whitty, C. J. M. Cost-effectiveness study of three antimalarial drug combinations in Tanzania. PLoS Med. 2006, 3, 1844-1850.
56. Fidock, D. A.; Rosenthal, P. J.; Croft, S. L.; Brun, R.; Nwaka, S. Antimalarial drug discovery: Efficacy models for compound screening. Nat. Rev. Drug Discovery 2004, 3, 509-520.
57. Robert, A.; Benoit-Vical, F.; Meunier, B. The key role of heme to trigger the antimalarial activity of trioxanes. Coord. Chem. Rev. 2005, 249, 1927-1936.
58. Dechy-Cabaret, O.; Benoit-Vical, F.; Robert, A.; Meunier, B. Preparation and antimalarial activities of "trioxaquines", new modular molecules with a trioxane skeleton linked to a 4-aminoquinoline. ChemBioChem 2000, 1, 281-283.
59. Robert, A.; Dechy-Cabaret, O.; Cazelles, J.; Meunier, B. From mechanistic studies on artemisinin derivatives to new modular antimalarial drugs. Acc. Chem. Res. 2002, 35, 167-174.
60. Dechy-Cabaret, O.; Benoit-Vical, F.; Loup, C.; Robert, A.; Gomitzka, H.; Bonhoure, A.; Vial, H.; Magnaval, J. F.; Séguéla, J. P.; Meunier, B. Synthesis and antimalarial activity of trioxaquine derivatives. Chemistry 2004, 10, 1625-1636.
61. Benoit-Vical, F.; Lelièvre, J.; Berry, A.; Deymier, C.; Dechy-Cabaret, O.; Cazelles, J.; Loup, C.; Robert, A.; Magnaval, J. F.; Meunier, B. Trioxaquines: New antimalarial agents active on all erythrocytic forms including gametocytes. Antimicrob. Agents Chemother. 2007, 51, 1463-1472.
62. Laurent, S. A.; Loup, C.; Mourgues, S.; Robert, A.; Meunier, B. Heme alkylate by the antimalarial endoperoxides artesunate and trioxaquine. ChemBioChem 2005, 6, 653-658.
63. Robert, A.; Bonduelle, C.; Laurent, S. A.; Meunier, B. Heme alkylation by artemisinin and trioxaquines. J. Phys. Org. Chem. 2006, 19, 562-569.
64. Vennerstrom, J. L.; Arbe-Barnes, S.; Brun, R.; Charman, S. A.; Chlu, F. C. K.; Chollet, J.; Dong, Y.; Dorn, A.; Hunziker, D.; Matile, H.; McIntosh, K.; Padmanilayam, M.; Tomas, J. S.; Scheurer, H.; Scorneaux, B.; Tang, Y.; Urwyler, H.; Wittlin, S.; Charman, W. N. Identification of an antimalarial synthetic trioxolane drug development candidate. Nature 2004, 430, 900-904.
65. Frantz, S. The trouble with making combination drugs. Nat. Rev. Drug Discovery 2006, 5, 881-882.
66. Morphy, R.; Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem. 2005, 48, 6523-6543.
67. Burgess, S. J.; Selzer, A.; Kelly, J. X.; Smilkstein, M. J.; Riscoe, M. K.; Peyton, D. H. A chloroquine-like molecule designed to reverse resistance in Plasmodium falciparum. J. Med. Chem. 2006, 49, 5623-5625.
68. Kogen, H.; Toda, N.; Tago, K.; Marumoto, S.; Takami, K.; Ori, M.; Yamada, N.; Koyama, K.; Naruto, S.; Abe, K.; Yamazaki, R.; Hara, T.; Aoyagi, A.; Abe, Y.; Kaneko, T. Design and synthesis of dual inhibitors of acetylcholinesterase and serotonin transporter targeting potential agents for Alzheimer's disease. Org. Lett. 2002, 4, 3359-3362.
69. Koufaki, M.; Theodorou, E.; Galaris, D.; Nousis, L.; Katsanou, E. S.; Alexis, M. N. Chroman/catechol hybrids: Synthesis and evaluation of their activity against oxidative stress induced cellular damage. J. Med. Chem. 2006, 49, 300-306.
70. Davioud-Charvet, E.; Delarue, S.; Biot, C.; Schwöbel, B.; Boehme, C. C.; Müssigbrodt, A.; Maes, L.; Sergheraert, C.; Grellier, P.; Schirmer, R. H.; Becker, K. A prodrug form of a Plasmodium falciparum glutathione reductase inhibitor conjugated with a 4-anilinoquinoline. J. Med. Chem. 2001, 44, 4268-4276.
71. Nakagawa-Goto, K.; Nakamura, S.; Bastow, K. F.; Nyarko, A.; Peng, C.-Y.; Lee, F.-Y.; Lee, F.-C.; Lee, K.-H. Antitumor agents. 256. Conjugation of paclitaxel with other antitumor agents: Evaluation of novel conjugates as cytotoxic agents. Bioorg. Med. Chem. Lett. 2007, 17, 2894-2898.
72. Dollinger, S.; Löber, S.; Klingenstein, R.; Korth, C.; Gmeiner, P. A chimeric ligand approach leading to potent antiprion active acridine derivatives: Design, synthesis, and biological investigations. J. Med. Chem. 2006, 49, 6591-6595.
73. Pratviel, G.; Bernadou, J.; Meunier, B. Carbon-hydrogen bonds of DNA sugar units as targets for chemical nucleases and drugs. Angew. Chem., Int. Ed. 1995, 34, 746-769.
74. Dervan, P. B.; Doss, R. M.; Marques, M. A. Programmable DNA binding oligomers for control of transcription. Curr. Med. Chem. Anticancer Agents 2005, 5, 373-378.
75. Bryskier, A. Dual β-lactam-fluoroquinolone compounds: A novel approach to antibacterial treatment. Expert Opin. Invest. Drugs 1997, 6, 1476-1499.